Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

BACKGROUND: Non–vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug Administration labeling), and outcomes of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinberg, Benjamin A., Shrader, Peter, Pieper, Karen, Thomas, Laine, Allen, Larry A., Ansell, Jack, Chan, Paul S., Ezekowitz, Michael D., Fonarow, Gregg C., Freeman, James V., Gersh, Bernard J., Kowey, Peter R., Mahaffey, Kenneth W., Naccarelli, Gerald V., Reiffel, James A., Singer, Daniel E., Peterson, Eric D., Piccini, Jonathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850192/
https://www.ncbi.nlm.nih.gov/pubmed/29453305
http://dx.doi.org/10.1161/JAHA.117.007633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850192/
https://www.ncbi.nlm.nih.gov/pubmed/29453305
http://dx.doi.org/10.1161/JAHA.117.007633

Ejemplares similares